Outcomes of Immunotherapy in Sinonasal Mucosal Melanoma Patients With Recurrent and Metastatic Disease.
immunotherapy
recurrence
sinonasal mucosal melanoma
Journal
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
ISSN: 1097-6817
Titre abrégé: Otolaryngol Head Neck Surg
Pays: England
ID NLM: 8508176
Informations de publication
Date de publication:
17 Jun 2024
17 Jun 2024
Historique:
revised:
20
05
2024
received:
17
02
2024
accepted:
29
05
2024
medline:
17
6
2024
pubmed:
17
6
2024
entrez:
17
6
2024
Statut:
aheadofprint
Résumé
Sinonasal mucosal melanoma (SNMM) is a rare malignancy with poor prognosis and high recurrence rate. In those with recurrence, survival is dismal. Immunotherapy is an emerging area of investigation; however, there is a scarcity of data on immunotherapy outcomes in SNMM patients with recurrence. We report outcomes of immunotherapy in recurrent SNMM patients with distant versus nondistant recurrence. Fifty-four patients with recurrent SNMM were identified, and 31 (57.4%) had distant recurrence. One-year overall survival (OS) following recurrence was 47.5% (95% confidence interval [CI]: 34.0%-60.9%), with a median survival of 2.8 years (95% CI: 2.0-5.3). In those with distant recurrence, receipt of immunotherapy was associated with better OS compared to those without immunotherapy (hazard ratio [HR] = 0.29 [95% CI: 0.12-0.68], P = .004). While patients with nondistant recurrence (n = 23), who received immunotherapy (n = 6) had worse OS compared to those who did not receive immunotherapy (HR = 4.76 [95% CI: 1.36, 15.89], P = .02). LEVEL OF EVIDENCE: Level IV.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 American Academy of Otolaryngology–Head and Neck Surgery Foundation.
Références
Ajmani GS, Liederbach E, Kyrillos A, Wang CH, Pinto JM, Bhayani MK. Adjuvant radiation and survival following surgical resection of sinonasal melanoma. Am J Otolaryngol. 2017;38(6):663‐667. doi:10.1016/j.amjoto.2017.08.010
Amit M, Tam S, Abdelmeguid AS, et al. Patterns of treatment failure in patients with sinonasal mucosal melanoma. Ann Surg Oncol. 2018;25(6):1723‐1729. doi:10.1245/s10434-018-6465-y
Low CM, Price DL, Moore EJ, et al. Nodal and distant metastases in sinonasal mucosal melanoma: a population‐based analysis. Laryngoscope. 2019;130(3):622‐627. doi:10.1002/lary.28065
Lechner M, Takahashi Y, Turri‐Zanoni M, et al. International multicenter study of clinical outcomes of sinonasal melanoma shows survival benefit for patients treated with immune checkpoint inhibitors and potential improvements to the current TNM staging system. J Neurol Surg B Skull Base. 2023;84(4):307‐319. doi:10.1055/s-0042-1750178
Gal TJ, Silver N, Huang B. Demographics and treatment trends in sinonasal mucosal melanoma. Laryngoscope. 2011;121(9):2026‐2033. doi:10.1002/lary.21925
Konuthula N, Khan MN, Parasher A, et al. The presentation and outcomes of mucosal melanoma in 695 patients. Int Forum Allergy Rhinol. 2017;7(1):99‐105. doi:10.1002/alr.21831
Gore M, Zanation A. Survival in sinonasal melanoma: a meta‐analysis. J Neurol Surg B Skull Base. 2012;73(3):157‐162. doi:10.1055/s-0032-1301400
Pandrangi VC, Mace JC, Abiri A, et al. Recurrence patterns among patients with sinonasal mucosal melanoma: a multi‐institutional study. Int Forum Allergy Rhinol. 2023;13(12):2156‐2164. doi:10.1002/alr.23204
Amit M, Tam S, Abdelmeguid AS, et al. Role of adjuvant treatment in sinonasal mucosal melanoma. J Neurol Surg. 2017;78(6):512‐518. doi:10.1055/s-0037-1604350
Moreno MA, Roberts DB, Kupferman ME, et al. Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson. Cancer. 2010;116(9):2215‐2223. doi:10.1002/cncr.24976
Abiri A, Yasaka TM, Lehrich BM, et al. Adjuvant therapy and prognosticators of survival in head and neck mucosal melanoma. Laryngoscope. 2021;132(3):584‐592. doi:10.1002/lary.29807
Samstein RM, Carvajal RD, Postow MA, et al. Localized sinonasal mucosal melanoma: outcomes and associations with stage, radiotherapy, and positron emission tomography response. Head Neck. 2016;38(9):1310‐1317. doi:10.1002/hed.24435
Kuan EC, Wang E, Adappa ND, et al. International consensus statement on allergy and rhinology: sinonasal tumors. Int Forum Allergy Rhinol. 2024;14(2):149‐608. doi:10.1002/alr.23262
Ganti A, Raman A, Shay A, et al. Treatment modalities in sinonasal mucosal melanoma: a national cancer database analysis. Laryngoscope. 2019;130(2):275‐282. doi:10.1002/lary.27995
Scherzad A, Stöth M, Meyer TJ, et al. Multimodal treatment and immune checkpoint inhibition in sinonasal mucosal melanoma: real‐world data of a retrospective, single‐center study. Eur Arch Otrhinolaryngol. 2023;280(9):4215‐4223. doi:10.1007/s00405-023-08015-8
Guo R, Jenkins SM, Johnson BJ, Reed K, Kroneman T, Choby G. Sinonasal mucosal melanoma: role of tumor proliferative indices and pathological factors in survival. Laryngoscope. 2022;132(12):2350‐2358. doi:10.1002/lary.30240
Johnson BJ, Guo R, Moore EJ, et al. Sinonasal mucosal melanoma: an analysis of treatment‐related adverse events and associated factors. Int Forum Allergy Rhinol. 2023;13(6):1037‐1041. doi:10.1002/alr.23118
D'Angelo SP, Larkin J, Sosman JA, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol. 2017;35(2):226‐235. doi:10.1200/jco.2016.67.9258